A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TQC2938 Injection in Healthy Adult Subjects After Single and Multiple Administration
Latest Information Update: 18 Jun 2024
At a glance
- Drugs TQC 2938 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 18 Jun 2024 New trial record